Methods for Treatment of Psoriatic Arthritis - Patent Application US20260108530A1
Summary
Three inventors — Pille Harrison, Luc Meuleners, and Chantal Thérèse Tasset — filed Application US20260108530A1 on 2025-05-13, published April 23, 2026, covering a compound according to Formula I, or a pharmaceutically acceptable salt, solvate, or salt of a solvate thereof, pharmaceutical compositions comprising the same, and methods of treatment using the same, for use in the treatment of psoriatic arthritis. The application is classified under CPC codes A61K 31/541 and A61P 19/02.
“The present invention relates to compound according to Formula I: or a pharmaceutically acceptable salt thereof, or a solvate or the salt of a solvate thereof, pharmaceutical compositions comprising the same, and methods of treatment using the same, for use in the treatment of psoriatic arthritis, by administering the compound according to Formula I.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
Application US20260108530A1, filed May 13, 2025 and published April 23, 2026, discloses a pharmaceutical compound according to Formula I and methods of using the compound in the treatment of psoriatic arthritis. The invention covers the compound itself, its pharmaceutical compositions, and therapeutic methods of administration for this indication.
Affected parties include the named inventors and their assignees seeking patent protection for the disclosed compound and treatment methods. Pharmaceutical companies developing treatments for psoriatic arthritis should monitor this application to assess potential freedom-to-operate implications or competitive landscape developments in this therapeutic area.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Application US20260108530A1 Kind: A1 Apr 23, 2026
Inventors
Pille Harrison, Luc Meuleners, Chantal Thérèse Tasset
Abstract
The present invention relates to compound according to Formula I: or a pharmaceutically acceptable salt thereof, or a solvate or the salt of a solvate thereof, pharmaceutical compositions comprising the same, and methods of treatment using the same, for use in the treatment of psoriatic arthritis, by administering the compound according to Formula I.
CPC Classifications
A61K 31/541 A61P 19/02
Filing Date
2025-05-13
Application No.
19206213
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.